The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic…
Articles by Marisa Wexler, MS
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo…
Metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, and other aging-related metabolic disorders may be…
An initiative in the European Union (EU) aims to speed up the diagnosis of rare genetic disorders such as…
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about…
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for…
An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a…
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from…
Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe —…